Decheng Capital
$661M Assets Reported
19 Holdings
Latest filing 2026-03-31
Top Holdings
| Ticker | Company | Shares | Value | Weight |
|---|---|---|---|---|
| CGON | CG ONCOLOGY INC | 6,371,669 | $431M | 65.2% |
| NUVB | Nuvation Bio Inc. | 25,954,439 | $111M | 16.8% |
| UPB | Upstream Bio Inc. | 2,724,868 | $25M | 3.7% |
| ACRS | Aclaris Therapeutics, Inc. | 4,041,736 | $15M | 2.3% |
| AARD | AARDVARK THERAPEUTICS INC | 3,917,299 | $15M | 2.2% |
| LYELXXXX | Lyell Immunopharma, Inc. | 692,050 | $14M | 2.1% |
| NAMS | NEWAMSTERDAM PHARMA CO NV | 325,057 | $10M | 1.6% |
| RCUS | Arcus Biosciences, Inc | 477,819 | $10M | 1.6% |
| RVMD | REVOLUTION MEDICINES INC(NSM) | 93,500 | $9M | 1.4% |
| EQ | Equillium Inc. | 4,447,308 | $9M | 1.3% |
Track Decheng Capital's 13F portfolio: $661M in reported holdings, 19 positions. Top holdings, AUM, and quarterly changes on SentiSense.